Colin Hughes prepares and prosecutes patent applications throughout the world to obtain patent protection in areas including biotechnology, chemistry, and pharmaceuticals. He provides clients with a broad range of services, including U.S. and foreign patent portfolio development and management, patentability and validity assessments, freedom to operate analysis, and patent strategy counseling.
He also has experience in post-grant proceedings, including inter partes review (IPR) and interference proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office, and opposition procedures before the European Patent Office. He has worked closely with expert witnesses in drafting declarations, designing experiments, and preparing for depositions.
Representative clients include Celgene Corporation and Idenix Pharmaceuticals (now Merck). Pharmaceutical products for which Colin has experience include Revlimid®, Pomalyst®, Otezla®, and Vidaza®.
Prior to practicing law, Colin obtained his Ph.D. in organic chemistry, conducting research in the area of total synthesis of natural products. During this time he performed complex multistep synthesis and prepared hundreds of compounds on scales ranging from milligram quantities up to 200 grams. One result of his research was the completion of the total synthesis of the proposed structure of aldingenin B.
- University of San Diego (J.D. 2016); University of North Carolina at Chapel Hill (Ph.D. in Organic Chemistry 2012); University of California, Berkeley (B.S. in Chemistry 2006)
- California, U.S. District Court for the Southern District of California, and registered to practice before the U.S. Patent and Trademark Office